Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel maintenance after nab-paclitaxel + carboplatin induction in squamous NSCLC
2014-003804-66Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nab-paclitaxel and carboplatin in Pulmonary squamous cell carcinoma (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started Jun 2015; status: completed.
02
Drugs
nab-paclitaxelcarboplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2014-003804-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003804-66.